Novel P2 Tris-tetrahydrofuran Group in Antiviral Compound 1 (GRL-0519) Fills the S2 Binding Pocket of Selected Mutants of HIV-1 Protease

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2013 Jan 10

PMID 23298236

Citations 18

Authors

Hongmei Zhang

Yuan-Fang Wang

Chen-Hsiang Shen

Johnson Agniswamy

Kalapala Venkateswara Rao

Chun-Xiao Xu

Arun K Ghosh

Robert W Harrison

Irene T Weber

Affiliations

Soon will be listed here.

Abstract

GRL-0519 (1) is a potent antiviral inhibitor of HIV-1 protease (PR) possessing tris-tetrahydrofuran (tris-THF) at P2. The high resolution X-ray crystal structures of inhibitor 1 in complexes with single substitution mutants PR(R8Q), PR(D30N), PR(I50V), PR(I54M), and PR(V82A) were analyzed in relation to kinetic data. The smaller valine side chain in PR(I50V) eliminated hydrophobic interactions with inhibitor and the other subunit consistent with 60-fold worse inhibition. Asn30 in PR(D30N) showed altered interactions with neighboring residues and 18-fold worse inhibition. Mutations V82A and I54M showed compensating structural changes consistent with 6-7-fold lower inhibition. Gln8 in PR(R8Q) replaced the ionic interactions of wild type Arg8 with hydrogen bond interactions without changing the inhibition significantly. The carbonyl oxygen of Gly48 showed two alternative conformations in all structures likely due to the snug fit of the large tris-THF group in the S2 subsite in agreement with high antiviral efficacy of 1 on resistant virus.

Citing Articles

Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations.

Belal A, Abdou A, Miski S, Ali M, Ghamry H, Obaidullah A Front Chem. 2025; 12:1521298.

PMID: 39886558 PMC: 11779707. DOI: 10.3389/fchem.2024.1521298.

HIV-1 protease with 10 lopinavir and darunavir resistance mutations exhibits altered inhibition, structural rearrangements and extreme dynamics.

Wong-Sam A, Wang Y, Kneller D, Kovalevsky A, Ghosh A, Harrison R J Mol Graph Model. 2022; 117:108315.

PMID: 36108568 PMC: 10091457. DOI: 10.1016/j.jmgm.2022.108315.

Phosphine-catalyzed divergent domino processes between γ-substituted allenoates and carbonyl-activated alkenes.

Wu M, Han Z, Ni H, Wang N, Ding K, Lu Y Chem Sci. 2022; 13(11):3161-3168.

PMID: 35414887 PMC: 8926293. DOI: 10.1039/d1sc06364b.

The Pseudo-Symmetric -benzyl Hydroxyethylamine Core in a New Series of Heteroarylcarboxyamide HIV-1 Pr Inhibitors: Synthesis, Molecular Modeling and Biological Evaluation.

DOrsi R, Funicello M, Laurita T, Lupattelli P, Berti F, Chiummiento L Biomolecules. 2021; 11(11).

PMID: 34827582 PMC: 8615997. DOI: 10.3390/biom11111584.

Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.

Laville P, Petitjean M, Regad L Molecules. 2021; 26(3).

PMID: 33503916 PMC: 7865771. DOI: 10.3390/molecules26030611.

References

Darke P, NUTT R, Brady S, Garsky V, Ciccarone T, Leu C . HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteins. Biochem Biophys Res Commun. 1988; 156(1):297-303. DOI: 10.1016/s0006-291x(88)80839-8. View

Kovalevsky A, Liu F, Leshchenko S, Ghosh A, Louis J, Harrison R . Ultra-high resolution crystal structure of HIV-1 protease mutant reveals two binding sites for clinical inhibitor TMC114. J Mol Biol. 2006; 363(1):161-73. PMC: 1781337. DOI: 10.1016/j.jmb.2006.08.007. View

Girard M, Bansal G . HIV/AIDS vaccines: a need for new concepts?. Int Rev Immunol. 2008; 27(6):447-71. DOI: 10.1080/08830180802432160. View

Pazhanisamy S, Stuver C, Cullinan A, Margolin N, Rao B, Livingston D . Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J Biol Chem. 1996; 271(30):17979-85. DOI: 10.1074/jbc.271.30.17979. View

Ho D, Toyoshima T, Mo H, Kempf D, Norbeck D, Chen C . Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol. 1994; 68(3):2016-20. PMC: 236669. DOI: 10.1128/JVI.68.3.2016-2020.1994. View

Mahalingam B, Boross P, Wang Y, Louis J, Fischer C, Tozser J . Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins. 2002; 48(1):107-16. DOI: 10.1002/prot.10140. View

Mahalingam B, Louis J, Reed C, Adomat J, Krouse J, Wang Y . Structural and kinetic analysis of drug resistant mutants of HIV-1 protease. Eur J Biochem. 1999; 263(1):238-45. DOI: 10.1046/j.1432-1327.1999.00514.x. View

Mahalingam B, Wang Y, Boross P, Tozser J, Louis J, Harrison R . Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem. 2004; 271(8):1516-24. DOI: 10.1111/j.1432-1033.2004.04060.x. View

Mitsuya Y, Winters M, Fessel W, Rhee S, Hurley L, Horberg M . N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. AIDS Res Hum Retroviruses. 2007; 22(12):1300-5. PMC: 2573402. DOI: 10.1089/aid.2006.22.1300. View

10.

Sheldrick G . A short history of SHELX. Acta Crystallogr A. 2007; 64(Pt 1):112-22. DOI: 10.1107/S0108767307043930. View

11.

Miller V . International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J Acquir Immune Defic Syndr. 2001; 26 Suppl 1:S34-50. DOI: 10.1097/00042560-200103011-00005. View

12.

Brenner B, Turner D, Wainberg M . HIV-1 drug resistance: can we overcome?. Expert Opin Biol Ther. 2002; 2(7):751-61. DOI: 10.1517/14712598.2.7.751. View

13.

McCoy A, Grosse-Kunstleve R, Storoni L, Read R . Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr. 2005; 61(Pt 4):458-64. DOI: 10.1107/S0907444905001617. View

14.

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

15.

Kovalevsky A, Tie Y, Liu F, Boross P, Wang Y, Leshchenko S . Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M. J Med Chem. 2006; 49(4):1379-87. PMC: 3015180. DOI: 10.1021/jm050943c. View

16.

Mahalingam B, Louis J, Hung J, Harrison R, Weber I . Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins. 2001; 43(4):455-64. DOI: 10.1002/prot.1057. View

17.

Kozisek M, Bray J, rezacova P, Saskova K, Brynda J, Pokorna J . Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants. J Mol Biol. 2007; 374(4):1005-16. DOI: 10.1016/j.jmb.2007.09.083. View

18.

Richman D, Morton S, Wrin T, Hellmann N, Berry S, Shapiro M . The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004; 18(10):1393-401. DOI: 10.1097/01.aids.0000131310.52526.c7. View

19.

Jarvis B, Faulds D . Nelfinavir. A review of its therapeutic efficacy in HIV infection. Drugs. 1998; 56(1):147-67. DOI: 10.2165/00003495-199856010-00013. View

20.

Weber I, Agniswamy J . HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses. 2011; 1(3):1110-36. PMC: 3185505. DOI: 10.3390/v1031110. View